IP Verse

Ucb Pharma patent opposition analysis

Get complete Patent Opposition Report for Ucb Pharma

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest oppositions filed by Ucb Pharma

Explore patent oppositions filed by Ucb Pharma against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP3345607Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABJul 26, 2023

Latest patents of Ucb Pharma opposed by its competitors

Explore Ucb Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP2301961Dec 13, 2023Sclerostin Epitopes1
EP3145504Jul 26, 2023Transdermal Delivery System Including An Interface Mediator1
EP2869844Jun 21, 2023Treatment For Bone Diseases1
EP2645997Aug 10, 2022Once Daily Formulation Of Lacosamide1
EP2345668Sep 22, 2021Sclerostin Epitopes1
EP3670528Sep 8, 2021Sclerostin Binding Agents1
EP2992891Aug 5, 2020Pharmaceutical Composition Comprising Brivaracetam And Lacosamide With Synergistic Anticonvulsant Effect1
EP2515887Jun 6, 2018Polyvinylpyrrolidone For The Stabilization Of A Solid Dispersion Of The Non-Crystalline Form Of Rotigotine2
EP2037965Aug 30, 2017Pharmaceutical Composition With Synergistic Anticonvulsant Effect1
EP2922533Jun 14, 2017Multi-Day Patch For The Transdermal Administration Of Rotigotine2

Top competitors of Ucb Pharma